Investigational drug · Phase 3
Lutikizumab
Also called: ABT-981
Not approved by FDA. In 8 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
8
8 still active
All registered trials
12
Any phase or sponsor naming "Lutikizumab"
First trial start
2021
Dec 28, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Lutikizumab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hidradenitis Suppurativa
- Atopic Dermatitis
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Ulcerative Colitis
- Crohn's Disease
Approved drugs for the same conditions: Rheumatoid arthritis · Psoriatic arthritis · Atopic dermatitis (eczema) · Crohn's disease · Ulcerative colitis · Hidradenitis suppurativa · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "Lutikizumab" as an intervention, largest first.
- A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis SuppurativaPivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT06468228 · 1,400 participants · Start Jun 27, 2024 · Primary completion Dec 2026
Drug: Lutikizumab; Placebo · For: Hidradenitis Suppurativa
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 279 sites in all
- Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's DiseasePivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT06548542 · 590 participants (planned) · Start Sep 4, 2024 · Primary completion Jan 2030
Drug: Risankizumab; Lutikizumab and 4 more · For: Crohn's Disease
Sites: Dothan, Alabama; Mobile, Alabama; Coronado, California · 255 sites in all
- A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee OsteoarthritisPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT02087904 · 350 participants · Start Jun 4, 2014 · Primary completion Jun 7, 2016
Drug: ABT-981 · For: Knee Osteoarthritis; Medial Compartment Knee Osteoarthritis
- Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic ArthritisPivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT06865105 · 300 participants (planned) · Start Apr 11, 2025 · Primary completion Aug 2029
Drug: Lutikizumab; Risankizumab and 2 more · For: Psoriatic Arthritis
Sites: Huntington Beach, California; Avon Park, Florida; Clearwater, Florida · 41 sites in all
- A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic TherapyPivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT05139602 · 210 participants · Start Dec 28, 2021 · Primary completion Dec 2027
Drug: Lutikizumab; Placebo · For: Hidradenitis Suppurativa
Sites: Phoenix, Arizona; Scottsdale, Arizona; Hot Springs, Arkansas · 54 sites in all
- A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid ArthritisPivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT06972446 · 180 participants (planned) · Start Jun 20, 2025 · Primary completion Feb 2027
Drug: Lutikizumab; Placebo and 1 more · For: Rheumatoid Arthritis
Sites: Peoria, Arizona; Jonesboro, Arkansas; Beverly Hills, California · 96 sites in all
- A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative ColitisPivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT06257875 · 156 participants · Start Mar 23, 2024 · Primary completion Sep 2027
Drug: Lutikizumab; Lutikizumab and 1 more · For: Ulcerative Colitis
Sites: Chula Vista, California; Coronado, California; Huntington Beach, California · 191 sites in all
- A Phase 2a Study Evaluating the Safety and Efficacy of ABT-981 in Patients With Erosive Hand OsteoarthritisPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT02384538 · 132 participants · Start Mar 2015 · Primary completion Jul 2016
Drug: ABT-981; Placebo for ABT-981 · For: Erosive Hand Osteoarthritis
- A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic DermatitisActive, not recruiting
AbbVieAbbVie (ABBV)
NCT06718101 · 83 participants · Start Dec 19, 2024 · Primary completion May 2027
Drug: Lutikizumab; Placebo · For: Atopic Dermatitis
Sites: Fountain Hills, Arizona; Los Angeles, California; Sacramento, California · 30 sites in all
AbbVieAbbVie (ABBV)
NCT06524635 · 60 participants (planned) · Start Aug 14, 2024 · Primary completion Feb 2027
Drug: Lutikizumab · For: Hidradenitis Suppurativa; Atopic Dermatitis
Sites: Sacramento, California; Ann Arbor, Michigan
Newest research
PubMed records naming it or its code names, newest first.
- Targeting Inflammation in Osteoarthritis Pain: A Phenotype-Driven Approach.
Zheng W, Huang C, Liu S, et al. · J Inflamm Res 2026
- Disease-modifying antirheumatic drugs for hand osteoarthritis: A systematic review and network meta-analysis.
Dong P, Zhao Q, Yang B, et al. · Hand Surg Rehabil 2026
- Lutikizumab in Adults With Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure: A Phase 2 Randomized Clinical Trial.
Kimball AB, Sawicki KT, Ackerman L, et al. · JAMA Dermatol 2026
- Evaluating the promotion of biomechanical changes in osteoarthritis treated with lutikizumab: a systematic review and meta-analysis.
Kou H, Liu H, Lai L, et al. · Postgrad Med 2026
- Efficacy and Safety of Medical Interventions for Moderate to Severe Hidradenitis Suppurativa: A Living Systematic Review and Network Meta-Analysis.
Garg A, Cohn E, Midgette B, et al. · JAMA Dermatol 2025
- Advances and Challenges in the Pursuit of Disease-Modifying Osteoarthritis Drugs: A Review of 2010-2024 Clinical Trials.
Brandt MD, Malone JB, Kean TJ · Biomedicines 2025
Also in development for Hidradenitis Suppurativa
- ZasocitinibTAK- 279, NDI-034858Phase 317 trials
Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease
- MK-7240PRA023, TulisokibartPhase 310 trials
Merck & Co. · Ulcerative Colitis, Psoriatic Arthritis, Crohn's Disease
- OlatorepatideHS-20094Phase 38 trials
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Type 2 Diabetes, Overweight or Obesity, Overweight or Obesity Without Diabetes
- SonelokimabPhase 37 trials
MoonLake Immunotherapeutics AG · Hidradenitis Suppurativa, Arthritis, Psoriatic
- brivekimigSAR442970Phase 25 trials
Sanofi · Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Type 1 Diabetes Mellitus
- MAS825ArumakimigPhase 24 trials
Novartis · NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations, Still´s Disease, VEXAS Syndrome
- EltrekibartLY3041658Phase 22 trials
Eli Lilly · Ulcerative Colitis, Ulcerative Colitis Chronic, Hidradenitis Suppurativa
- HB0043Phase 22 trials
Shanghai Huaota Biopharmaceutical Co., Ltd. · Acne Vulgaris, Hidradenitis Suppurativa
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AbbVie.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.